BURDEN OF DISEASE OF THE MASTOCARCINOMA IN AUSTRIA
Author(s)
Bauer M
The Institute for Pharmaeconomic research, Vienna, Austria
OBJECTIVES Breast cancer or rather called mastocarcinoma, is a malignant growth of the mammary gland. With an incidence rate of 5.105 people in 2010, breast cancer is the most frequent cancer disease in Austria. Annually about 1.500 cases of death are registered, therefore breast cancer is the leading cause for death among women. As a result, enormous costs arise for the health care system. Hence, the aim of the analysis was to evaluate the cost and disease burden of breast cancer. METHODS A burden of disease study, which evaluates all kinds of disease burden, like costs, quality adjusted life years (QALYs) and disability adjusted life years (DALYs) lost, was conducted. This analysis had an incidence based approach and projects costs over a time horizon of one year. Data were collected via literature review, published list prices and hospital records. Costs from published sources were used from the societal perspective. The direct costs include hospital, treatment and physician consultation costs. Indirect costs cover patient care giver costs as well as work absenteeism. RESULTS Each breast cancer patient causes direct costs of 6,423.91 EUR and indirect costs of 37,511.87 EUR. Due to the fact that not only costs are important for the health care systems, the mortality rate, QALYs and DALYs were identified. The mortality rate of breast cancer conducts 7.7 percent of all cancer deaths in Austria. Compared to the healthy population, a breast cancer patient has average utility decrements of 0.11. With regard to an incidence rate of 5.105 people in 2010, a breast cancer patient will lose 0.03 DALYs within one year. CONCLUSIONS The analysis showed that the treatment of new diagnosed breast cancer patients causes about 225.5 million EUR. Moreover patients had a lower QALY of 561,55 and a loss of 153,15 DALYs within one year.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCN76
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology